EA200000872A1 - Способы лечения диабета с помощью пептидных аналогов инсулина - Google Patents

Способы лечения диабета с помощью пептидных аналогов инсулина

Info

Publication number
EA200000872A1
EA200000872A1 EA200000872A EA200000872A EA200000872A1 EA 200000872 A1 EA200000872 A1 EA 200000872A1 EA 200000872 A EA200000872 A EA 200000872A EA 200000872 A EA200000872 A EA 200000872A EA 200000872 A1 EA200000872 A1 EA 200000872A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin
help
methods
treating diabetes
peptide analogues
Prior art date
Application number
EA200000872A
Other languages
English (en)
Other versions
EA003944B1 (ru
Inventor
Амитабх Гаур
Николас Линг
Пол Дж. Конлон
Original Assignee
Ньюрокрайн Байосайенсиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрокрайн Байосайенсиз Инк. filed Critical Ньюрокрайн Байосайенсиз Инк.
Publication of EA200000872A1 publication Critical patent/EA200000872A1/ru
Publication of EA003944B1 publication Critical patent/EA003944B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Настоящее изобретение относится к пептидным аналогам В-цепи инсулина, которые получены, главным образом, из пептидов, включающих остатки (9-23) последовательности нативной В-цепи. Эти аналоги отличаются от нативной последовательности в положениях 12, 13, 15 и/или 16 и могут дополнительно отличаться от нее в положении 19 и/или других положениях. Представлены фармацевтические композиции, содержащие эти пептидные аналоги. Эти пептидные аналоги пригодны для лечения и ингибирования развития диабета.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000872A 1998-02-23 1999-02-23 Способы лечения диабета с помощью пептидных аналогов инсулина EA003944B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (2)

Publication Number Publication Date
EA200000872A1 true EA200000872A1 (ru) 2001-02-26
EA003944B1 EA003944B1 (ru) 2003-10-30

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000872A EA003944B1 (ru) 1998-02-23 1999-02-23 Способы лечения диабета с помощью пептидных аналогов инсулина

Country Status (20)

Country Link
US (1) US6197926B1 (ru)
EP (1) EP1056776A1 (ru)
JP (1) JP2002504491A (ru)
KR (1) KR20010041238A (ru)
CN (1) CN1241942C (ru)
AP (1) AP2000001888A0 (ru)
AU (1) AU741037B2 (ru)
BR (1) BR9908178A (ru)
CA (1) CA2321929A1 (ru)
EA (1) EA003944B1 (ru)
HU (1) HUP0100928A3 (ru)
ID (1) ID26788A (ru)
IL (1) IL137904A0 (ru)
NO (1) NO20004198L (ru)
NZ (1) NZ506447A (ru)
OA (1) OA11453A (ru)
PL (1) PL342517A1 (ru)
SK (1) SK12412000A3 (ru)
TR (1) TR200003048T2 (ru)
WO (1) WO1999042482A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
JP2006502213A (ja) 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用
EP1660110A2 (en) * 2003-06-02 2006-05-31 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP5694779B2 (ja) 2008-01-09 2015-04-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
AU2009335712B2 (en) * 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
PT2498801T (pt) 2009-11-13 2018-05-02 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US10385107B2 (en) 2014-09-24 2019-08-20 Indiana Univeresity Researc and Technology Corporation Lipidated amide-based insulin prodrugs
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
DE69630527T2 (de) * 1995-06-30 2004-08-05 Novo Nordisk A/S Vorbeugung einer krankheit mit diabetes charakter

Also Published As

Publication number Publication date
NZ506447A (en) 2002-11-26
AU741037B2 (en) 2001-11-22
SK12412000A3 (sk) 2002-05-09
CN1294597A (zh) 2001-05-09
CA2321929A1 (en) 1999-08-26
PL342517A1 (en) 2001-06-18
WO1999042482A1 (en) 1999-08-26
BR9908178A (pt) 2002-01-15
NO20004198L (no) 2000-10-20
JP2002504491A (ja) 2002-02-12
AP2000001888A0 (en) 2000-09-30
KR20010041238A (ko) 2001-05-15
EA003944B1 (ru) 2003-10-30
TR200003048T2 (tr) 2000-12-21
HUP0100928A3 (en) 2001-11-28
NO20004198D0 (no) 2000-08-22
US6197926B1 (en) 2001-03-06
CN1241942C (zh) 2006-02-15
HUP0100928A2 (hu) 2001-08-28
IL137904A0 (en) 2001-10-31
AU2783199A (en) 1999-09-06
OA11453A (en) 2003-12-08
EP1056776A1 (en) 2000-12-06
ID26788A (id) 2001-02-08

Similar Documents

Publication Publication Date Title
EA200000872A1 (ru) Способы лечения диабета с помощью пептидных аналогов инсулина
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA200001071A1 (ru) Способ получения полимер-связанных циклических пептидов
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
CY1105452T1 (el) Παραγωγα της κυκλοσπορινης και μεθοδος παρασκευης των εν λογω παραγωγων
EA199901025A1 (ru) Пептидные аналоги паратиреоидного гормона
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
ATE549028T1 (de) Stabile analoga von glp-1
CY1106781T1 (el) Περιορισμενα ως προς τη διαμορφωση κυκλοποιημενα στην κυρια αλυσιδα αναλογα σωματοστατινης
BR9714200A (pt) Análogos de hormÈnio paratiróide
MD960317A (ru) Новые пептиды-агонисты амилина и их применение
DK0775160T3 (da) Cycliske hexapeptidsomatostatin-analoger
ATE299936T1 (de) Fas antigen-derivate
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
RU2009147217A (ru) Новые противоопухолевые соединения
DE69320967D1 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
KR880013977A (ko) 항응고제인 사이클릭 펩타이드
GB9606040D0 (en) Active peptide
ES2095255T3 (es) Analogos de sustitucion de peptidos magainina.
KR880013976A (ko) 항응고제인 사이클릭 펩타이드
AU2486800A (en) Pth functional domain conjugate peptides, derivatives thereof and novel tetheredligand-receptor molecules
EA200000709A1 (ru) Бета-липотропин и его применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU